Grifols SA
MAD:GRF

Watchlist Manager
Grifols SA Logo
Grifols SA
MAD:GRF
Watchlist
Price: 9.24 EUR 0.41% Market Closed
Market Cap: 6.3B EUR
Have any thoughts about
Grifols SA?
Write Note

Grifols SA
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Grifols SA
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Grifols SA
MAD:GRF
Net Issuance of Common Stock
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Net Issuance of Common Stock
-€2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Mar SA
MAD:PHM
Net Issuance of Common Stock
-€13.5m
CAGR 3-Years
-37%
CAGR 5-Years
-137%
CAGR 10-Years
-22%
Biotechnology Assets SA
MAD:BST
Net Issuance of Common Stock
-€462.7k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Grifols SA
Glance View

Market Cap
6.3B EUR
Industry
Biotechnology

Grifols SA, a global healthcare giant based in Barcelona, Spain, has carved its niche in the world through its pioneering work with plasma-derived medicines. Founded in 1940, the company has grown from a small family business into one of the world leaders in the production and development of biopharmaceuticals, particularly those derived from human plasma. Grifols operates a robust network of plasma donation centers, primarily in the United States, where it sources its primary raw material. The company's meticulous process involves collecting plasma from donors, which is then transported to sophisticated manufacturing facilities. Here, this vital fluid is fractionated into various components used to create life-saving treatments. These treatments address a spectrum of conditions, including hemophilia, immune deficiencies, and neurological issues, highlighting Grifols' integral role in advancing healthcare solutions. Grifols' business model is astutely designed to capitalize on the high demand for plasma-derived therapies, ensuring a steady stream of revenue. By vertically integrating its operations—from plasma collection through to product distribution—Grifols maintains stringent quality control and operational efficiency, driving down costs and enhancing margins. The company's segmentation includes Bioscience, which focuses on plasma-derived therapies; Diagnostic, which involves manufacturing tools and reagents for clinical analysis; and Hospital, which manages pharmacy and healthcare logistics products. Furthermore, the company has ventured into bio supplies, supplying biological materials for non-therapeutic use to life-science research. With a deep commitment to innovation and strategic acquisitions, Grifols stays ahead in the competitive biopharmaceutical landscape while fostering a direct link between donor generosity and patient needs, ensuring that its growth story has a profound impact on global health.

GRF Intrinsic Value
23.96 EUR
Undervaluation 61%
Intrinsic Value
Price

See Also

What is Grifols SA's Net Issuance of Common Stock?
Net Issuance of Common Stock
0 EUR

Based on the financial report for Dec 31, 2023, Grifols SA's Net Issuance of Common Stock amounts to 0 EUR.

Back to Top